Acute Myeloid Leukemia Clinical Trial

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Summary

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

View Full Description

Full Description

This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM-003 dose levels when administered to subjects with previously treated relapsed or refractory cute Myeloid Leukemia (AML).

Subjects will self-administer oral LAM-003 either once or twice per day as long as they are safely benefitting from therapy. Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels of LAM-003 using a standard 3+3 dose-escalation design. Based on the pattern of dose-limiting toxicities observed in the first 4 weeks of therapy, escalation will proceed to define a recommended LAM-003 dosing regimen.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and women of age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Presence of measurable AML that has progressed during or relapsed after prior therapy
All acute toxic effects of any prior antitumor therapy resolved to Grade 1.
Adequate hepatic profile.
Adequate renal function.
Adequate coagulation profile.
Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
For female subjects of childbearing potential, a negative serum pregnancy test.
For both male and female subjects, willingness to use adequate contraception.
Willingness and ability of the subject to comply with study activities.
Evidence of a personally signed informed consent document.

Exclusion Criteria:

Leukemic blast cell count >50 × 10^9/L before the start of study therapy and despite the use hydroxyurea, cytarabine, and/or cyclophosphamide.
Presence of known central nervous system (CNS) leukemia.
Presence of another major cancer.
Ongoing Grade >1 proliferative or nonproliferative retinopathy.
Significant cardiovascular disease or ECG abnormalities.
Significant gastrointestinal disease
Uncontrolled ongoing infection.
Pregnancy or breastfeeding.
Major surgery within 4 weeks before the start of study therapy.
Subject was a candidate for hematopoietic stem cell transplantation (HSCT).
Ongoing severe graft-versus-house disease (GVHD) with Grade ≥2 serum bilirubin, Grade ≥3 skin involvement, or Grade ≥3 diarrhea at the start of study therapy.
Prior solid organ transplantation.
Ongoing immunosuppressive therapy other than corticosteroids.
Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.
Use of a drug known to prolong the cardiac QT interval.
Concurrent participation in another therapeutic or imaging clinical trial.
Presence of a concomitant medical condition that (in the judgement of the investigator) interferes with the ability of the subject to participate in the study.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

17

Study ID:

NCT03426605

Recruitment Status:

Completed

Sponsor:

OrphAI Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Yale University
New Haven Connecticut, 06511, United States
University of Maryland
Baltimore Maryland, 21201, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Hackensack Meridien Health
Hackensack New Jersey, 07601, United States
Weill Cornell Medical College
New York New York, 10021, United States
Virginia Cancer Specialists
Fairfax Virginia, 22031, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

17

Study ID:

NCT03426605

Recruitment Status:

Completed

Sponsor:


OrphAI Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.